NDC-11 (Package) | NDC-9 (Product) (Ascending) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
21695-0896-10 | 21695-0896 | Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 10.0 mg/1 | Hormonal Therapy | Progestin | Oral | Aug. 9, 1996 | In Use | ||
21695-0896-20 | 21695-0896 | Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 10.0 mg/1 | Hormonal Therapy | Progestin | Oral | Aug. 9, 1996 | In Use | ||
21695-0896-30 | 21695-0896 | Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 10.0 mg/1 | Hormonal Therapy | Progestin | Oral | Aug. 9, 1996 | In Use | ||
21695-0952-05 | 21695-0952 | Methylprednisolone Acetate | Depo-Medrol | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intralesional, Intramuscular, Intrasynovial, Soft Tissue | May 28, 1959 | In Use | |
21695-0990-30 | 21695-0990 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | July 1, 2010 | In Use | ||
21922-0041-12 | 21922-0041 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | Nov. 6, 2023 | In Use | |
23155-0013-01 | 23155-0013 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | Nov. 5, 2010 | Sept. 23, 2019 | In Use | |
23155-0014-01 | 23155-0014 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Nov. 5, 2010 | Sept. 23, 2019 | In Use | |
23155-0014-05 | 23155-0014 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Nov. 5, 2010 | Sept. 23, 2019 | In Use | |
23155-0015-01 | 23155-0015 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Nov. 5, 2010 | Sept. 23, 2019 | In Use | |
23155-0168-31 | 23155-0168 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Dec. 13, 2012 | Aug. 12, 2020 | In Use |
23155-0170-31 | 23155-0170 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Aug. 31, 2023 | In Use | ||
23155-0179-31 | 23155-0179 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | June 20, 2012 | In Use | |
23155-0179-32 | 23155-0179 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | June 20, 2012 | June 21, 2012 | In Use |
23155-0196-31 | 23155-0196 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jan. 18, 2013 | In Use | |
23155-0196-41 | 23155-0196 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jan. 18, 2013 | In Use | |
23155-0196-42 | 23155-0196 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jan. 18, 2013 | In Use | |
23155-0196-43 | 23155-0196 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jan. 18, 2013 | July 31, 2020 | In Use |
23155-0213-31 | 23155-0213 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 200.0 mg/5mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Oct. 22, 2012 | Aug. 11, 2020 | No Longer Used |
23155-0214-31 | 23155-0214 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 1.0 g/25mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Oct. 22, 2012 | Aug. 11, 2020 | In Use |
23155-0240-41 | 23155-0240 | Metoclopramide Hydrochloride | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Jan. 3, 2014 | In Use | |
23155-0240-42 | 23155-0240 | Metoclopramide Hydrochloride | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Jan. 3, 2014 | In Use | |
23155-0240-43 | 23155-0240 | Metoclopramide Hydrochloride | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Jan. 3, 2014 | In Use | |
23155-0261-41 | 23155-0261 | Carmustine | BiCNU | Chemotherapy | Alkylating Agent | Nitrosourea | Intravenous | April 4, 2013 | Aug. 31, 2022 | No Longer Used | |
23155-0356-32 | 23155-0356 | Palonosetron Hydrochloride | Palonosetron Hydrochloride | 0.05 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | June 29, 2021 | June 30, 2021 | In Use |
23155-0356-41 | 23155-0356 | Palonosetron Hydrochloride | Palonosetron Hydrochloride | 0.05 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | June 29, 2021 | June 30, 2021 | In Use |
23155-0377-31 | 23155-0377 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Feb. 24, 2014 | Oct. 11, 2019 | In Use |
23155-0378-31 | 23155-0378 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Feb. 19, 2014 | Oct. 11, 2019 | In Use |
23155-0378-41 | 23155-0378 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Feb. 19, 2014 | Oct. 11, 2019 | In Use |
23155-0378-42 | 23155-0378 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Feb. 19, 2014 | Oct. 11, 2019 | In Use |
23155-0483-31 | 23155-0483 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 200.0 mg/5mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Oct. 22, 2012 | Oct. 11, 2019 | In Use |
23155-0484-31 | 23155-0484 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 1.0 g/25mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Oct. 22, 2012 | Oct. 11, 2019 | In Use |
23155-0528-31 | 23155-0528 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 200.0 mg/5mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Oct. 22, 2012 | Oct. 11, 2019 | No Longer Used |
23155-0529-31 | 23155-0529 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 1.0 g/25mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Oct. 22, 2012 | Oct. 11, 2019 | In Use |
23155-0547-31 | 23155-0547 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Aug. 22, 2016 | In Use | |
23155-0547-41 | 23155-0547 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | June 15, 2012 | In Use | |
23155-0547-42 | 23155-0547 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | June 15, 2012 | In Use | |
23155-0548-31 | 23155-0548 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Aug. 22, 2016 | In Use | |
23155-0548-41 | 23155-0548 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov. 9, 2015 | In Use | |
23155-0548-42 | 23155-0548 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov. 9, 2015 | In Use | |
23155-0549-31 | 23155-0549 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | June 15, 2012 | In Use | |
23155-0550-31 | 23155-0550 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov. 9, 2015 | In Use | |
23155-0649-41 | 23155-0649 | CARMUSTINE | CARMUSTINE | Chemotherapy | Alkylating Agent | Nitrosourea | Intravenous | Oct. 1, 2019 | In Use | ||
23155-0685-31 | 23155-0685 | Octreotide Acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 25, 2022 | In Use | ||
23155-0686-31 | 23155-0686 | Octreotide Acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 25, 2022 | In Use | ||
23155-0687-41 | 23155-0687 | OCTREOTIDE ACETATE | OCTREOTIDE ACETATE | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Sept. 3, 2019 | In Use | ||
23155-0688-41 | 23155-0688 | OCTREOTIDE ACETATE | OCTREOTIDE ACETATE | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Sept. 3, 2019 | In Use | ||
23155-0689-41 | 23155-0689 | OCTREOTIDE ACETATE | OCTREOTIDE ACETATE | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Sept. 3, 2019 | In Use | ||
23155-0774-71 | 23155-0774 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | June 15, 2022 | June 15, 2022 | No Longer Used |
23155-0774-72 | 23155-0774 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | June 15, 2022 | June 15, 2022 | No Longer Used |
23155-0775-71 | 23155-0775 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | June 15, 2022 | June 15, 2022 | No Longer Used |
23155-0775-72 | 23155-0775 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | June 15, 2022 | June 15, 2022 | No Longer Used |
23155-0776-71 | 23155-0776 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | June 15, 2022 | June 15, 2022 | No Longer Used |
23155-0776-72 | 23155-0776 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | June 15, 2022 | June 15, 2022 | No Longer Used |
23155-0777-71 | 23155-0777 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | June 15, 2022 | June 15, 2022 | No Longer Used |
23155-0777-72 | 23155-0777 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | June 15, 2022 | June 15, 2022 | No Longer Used |
23155-0778-71 | 23155-0778 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | June 15, 2022 | June 15, 2022 | No Longer Used |
23155-0778-72 | 23155-0778 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | June 15, 2022 | June 15, 2022 | No Longer Used |
23155-0779-71 | 23155-0779 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | June 15, 2022 | June 15, 2022 | No Longer Used |
23155-0790-41 | 23155-0790 | CARMUSTINE | CARMUSTINE | Chemotherapy | Alkylating Agent | Nitrosourea | Intravenous | March 1, 2021 | In Use | ||
23155-0857-03 | 23155-0857 | Anastrozole Tablets | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Feb. 28, 2019 | In Use | ||
23155-0857-05 | 23155-0857 | Anastrozole Tablets | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Feb. 28, 2019 | In Use | ||
23155-0857-09 | 23155-0857 | Anastrozole Tablets | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Feb. 28, 2019 | In Use | ||
23155-0869-41 | 23155-0869 | Arsenic Trioxide | Arsenic Trioxide | 2.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Oct. 7, 2021 | In Use | |
23155-0870-41 | 23155-0870 | Arsenic Trioxide | Arsenic Trioxide | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | April 22, 2022 | In Use | |
23155-0875-03 | 23155-0875 | Letrozole Tablets | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | June 1, 2023 | In Use | ||
23155-0875-09 | 23155-0875 | Letrozole Tablets | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | June 1, 2023 | In Use | ||
23155-0875-10 | 23155-0875 | Letrozole Tablets | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | June 1, 2023 | In Use | ||
23155-0882-31 | 23155-0882 | Paclitaxel | PACLITAXEL | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 31, 2023 | In Use | |
23155-0883-31 | 23155-0883 | Paclitaxel | PACLITAXEL | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 31, 2023 | In Use | |
23155-0884-31 | 23155-0884 | Paclitaxel | PACLITAXEL | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 31, 2023 | In Use | |
23594-0505-01 | 23594-0505 | Prednisolone | Millipred | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 1, 2014 | In Use | |
23594-0505-02 | 23594-0505 | Prednisolone | Millipred | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 16, 2016 | June 30, 2020 | In Use |
23594-0505-21 | 23594-0505 | Prednisolone | Millipred | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 1, 2014 | June 30, 2020 | In Use |
23594-0505-48 | 23594-0505 | Prednisolone | Millipred | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 1, 2014 | June 30, 2020 | In Use |
23594-0505-50 | 23594-0505 | Prednisolone | Millipred | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 21, 2016 | June 30, 2020 | In Use |
23594-0510-08 | 23594-0510 | Prednisolone Sodium Phosphate | Millipred | 10.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 1, 2014 | May 31, 2018 | In Use |
23594-0915-08 | 23594-0915 | Prednisolone Sodium Phosphate | Veripred 20 | 20.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 1, 2014 | June 30, 2018 | In Use |
24201-0101-04 | 24201-0101 | Valrubicin Intravesical Solution | Valrubicin Intravesical Solution | 40.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravesical | April 23, 2019 | In Use | |
24201-0237-01 | 24201-0237 | Fludarabine Phosphate | Fludarabine Phosphate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Dec. 13, 2017 | In Use | |
24236-0107-03 | 24236-0107 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 26, 2015 | Oct. 26, 2016 | No Longer Used |
24236-0205-20 | 24236-0205 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 13, 2011 | Dec. 13, 2012 | No Longer Used |
24236-0217-13 | 24236-0217 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 20, 2013 | Sept. 20, 2014 | No Longer Used |
24236-0217-55 | 24236-0217 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb. 7, 2013 | Sept. 13, 2014 | No Longer Used |
24236-0217-58 | 24236-0217 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 30, 2013 | June 24, 2014 | No Longer Used |
24236-0248-03 | 24236-0248 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 29, 2013 | Dec. 10, 2014 | No Longer Used |
24236-0248-10 | 24236-0248 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 11, 2013 | Oct. 11, 2014 | No Longer Used |
24236-0248-13 | 24236-0248 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 28, 2012 | May 15, 2015 | No Longer Used |
24236-0248-53 | 24236-0248 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 27, 2013 | Aug. 27, 2014 | No Longer Used |
24236-0248-58 | 24236-0248 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 12, 2013 | Sept. 12, 2014 | No Longer Used |
24236-0405-02 | 24236-0405 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | June 22, 2017 | June 9, 2018 | No Longer Used |
24236-0418-03 | 24236-0418 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 10, 2014 | Dec. 7, 2016 | No Longer Used |
24236-0418-13 | 24236-0418 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 23, 2016 | Dec. 8, 2016 | No Longer Used |
24236-0418-53 | 24236-0418 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 22, 2014 | Oct. 22, 2015 | No Longer Used |
24236-0418-55 | 24236-0418 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 11, 2014 | Dec. 7, 2016 | No Longer Used |
24236-0418-58 | 24236-0418 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 10, 2014 | Dec. 8, 2016 | No Longer Used |
24236-0625-04 | 24236-0625 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 18, 2012 | Sept. 18, 2013 | No Longer Used |
24236-0625-13 | 24236-0625 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 7, 2012 | Nov. 7, 2013 | No Longer Used |
24236-0625-20 | 24236-0625 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 22, 2013 | March 22, 2014 | No Longer Used |
24338-0050-08 | 24338-0050 | Carmustine | Gliadel | 7.7 mg/1 | Chemotherapy | Alkylating Agent | Nitrosourea | Intracavitary | Dec. 13, 2012 | In Use |
Found 10,000 results in 8 milliseconds — Export these results